Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2002

View Archived Issues

Simvastatin inhibits thrombin-induced tissue factor expression via the Rho/Rho kinase pathway

British Biotech presents development highlights over the last year

Efficacy of T-3811ME against meningitis caused by penicillin-resistant pneumococci

Procyon and Chiron extend PSP94 technology option agreement

ETX-100 granted orphan drug designation in alpha1-antitrypsin deficiency

Guilford initiates phase II trial of Aquavan in surgical patients

Phase II begins for irofulven + irinotecan in advanced gastrointestinal solid tumors

Selective adenosine A3 receptor ligand reduces IOP in monkeys

Second genomics-derived drug from HGS/GSK collaboration enters clinical testing

Mexiletine homodimers with superior analgesic profile

In vitro and in vivo pharmacology of EGIS-8332, a new neuroprotective agent

Salicylic acid analogues with IL-4-antagonist activity identified at Sunesis

Aventis presents new antiarrhythmic potassium channel blockers

Mechanism of action of cognition enhancer CGP-36742/DVD-742

Glycine-site NMDA modulators and their use claimed in Gruenenthal patent

Novel p38alpha kinase inhibitors in early development at Scios

Vita-Invest claims dual 5-HT reuptake inhibitors/5-HT1A receptor modulators

Adenosine A1 antagonists and their use in hypertension and other disorders

Novel anti-HIV agents in the Roche pipeline

Japanese partners withdraw potential RA therapeutic from development

Zonagen regains Vasomax rights, submits data from mechanistic trial

Effects of BIBN-4096BS on hemodynamic changes induced by capsaicin

Xenical label in E.U. changed to include data on overweight or obese type 2 diabetes patients

Yamanouchi licenses North American development and marketing rights to Z-338

Elitek approved in U.S.

AIT-034 and piracetam possess different profiles of activity in animal models of cognition

Mild cognitive impairment: state-of-the-art seminar